Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
Phase I Clinical Trial of Delta-24-RGD oncolytic adenovirus and
temozolomide for treatment of glioblastoma at first recurrence

Proposed period of release:
01/04/2013 to 01/04/2015

Name of the Institute(s) or Company(ies)
ClĂ­nica Universidad de Navarra, ;

3. Is the same GMO release planned elsewhere in the Community?

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Genus: Mastadenovirus
Species: human adenovirus

The GMO (Delta24-RGD-4C) is an oncolytic adenovirus, which is a replication competent virus selective of tumoral cells. Its genome contains 2 genetic modifications with respect to the wildtypevirus (Ad5).

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
Adenovirus human serotype 5 (Ad5)Mastadenovirushuman adenovirussubgroup Chuman serotype 5 (Ad5)-

European Commission administrative information

Consent given by the Member State Competent Authority:
17/05/2013 00:00:00